Dima Sharkawi-El

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 63 publications

Prior anti-BCMA antibody-drug conjugate exposure does not impact long-term outcomes with subsequent anti-BCMA T-cell-engaging bispecific antibodies: a singlecenter real-world data analysis.

Prior anti-BCMA antibody-drug conjugate exposure does not impact long-term outcomes with subsequent anti-BCMA T-cell-engaging bispecific antibodies: a singlecenter real-world data analysis.

Journal: Haematologica
Published: June 06, 2026

The diagnosis and management of primary mediastinal B-cell lymphoma: A British Society for Haematology guideline.

The diagnosis and management of primary mediastinal B-cell lymphoma: A British Society for Haematology guideline.

Journal: British journal of haematology
Published: April 03, 2026

Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing.

Glofitamab and epcoritamab for large B cell lymphoma: a real-world retrospective UK analysis of efficacy, tolerability, and impact of treatment sequencing.

Journal: Haematologica
Published: January 21, 2026

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Journal: Blood
Published: January 05, 2026

Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant.

Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant.

Journal: Blood
Published: January 05, 2026

Outcomes of second-line axicabtagene ciloleucel for large B-cell lymphoma in the UK.

Outcomes of second-line axicabtagene ciloleucel for large B-cell lymphoma in the UK.

Journal: HemaSphere
Published: September 05, 2025

Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma.

Treatment-related Outcomes and Patterns of Relapse in Secondary CNS Involvement by Large B-cell Lymphoma.

Journal: Blood
Published: September 02, 2025

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter's transformation.

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter's transformation.

Journal: Blood advances
Published: August 05, 2025

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation.

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter transformation.

Journal: Blood advances
Published: August 05, 2025

Epcoritamab for Relapsed/Refractory EBV+ Post-Transplant Lymphoproliferative Disorder of DLBCL-Type.

Epcoritamab for Relapsed/Refractory EBV+ Post-Transplant Lymphoproliferative Disorder of DLBCL-Type.

Journal: EJHaem
Published: July 03, 2025

International Consensus Criteria for the Diagnosis, Treatment Initiation, and Response Assessment for T-LGL Leukemia.

International Consensus Criteria for the Diagnosis, Treatment Initiation, and Response Assessment for T-LGL Leukemia.

Journal: Blood
Published: June 25, 2025

Diagnosis and Management of Large Granular Lymphocytic Leukaemia and Its Differentiation From T Cell Clones of Uncertain Significance.

Diagnosis and Management of Large Granular Lymphocytic Leukaemia and Its Differentiation From T Cell Clones of Uncertain Significance.

Journal: Hematological oncology
Published: March 31, 2025
Showing 1-12 of 63

Last Updated: 09/26/2026